Serum Soluble-Fms-Like Tyrosine Kinase 1-To-Placental Growth Factor Ratio on Elecsys Immunoassay Platform Predicts Preeclampsia With Severe Features in Hospitalized Women With Hypertensive Disorders of Pregnancy
( Am J Obstet Gynecol. 2026;234(3):834-855. doi: 10.1016/j.ajog.2025.11.006) Hypertensive disorders of pregnancy (HDP) include preeclampsia (PEC), eclampsia (EC), gestational hypertension (gHTN), and others, and PEC in particular affects between 5% and 8% of pregnancies in the United States. PEC rates in the United States have been increasing with the increase in average maternal age and obesity rates. The only effective treatment for PEC is delivery, and current recommendations focus on close monitoring for progression to PEC with severe features (sPEC), which can lead to both maternal and neonatal complications if not treated urgently. Progression to sPEC can be unpredictable, which supports close monitoring of both mother and fetus when HDP is present before the pregnancy has reached term. Recent research has shown that the biomarker of serum plasma soluble fms-like tyrosine kinase 1-to-placental growth factor (sFlt-1/PlGF) ratio is useful as an adjunct to other standard tools to predict the short-term development of sPEC and related outcomes. This study was designed to determine if a more accessible test (Elecsys sFlt-1/PlGF ratio assays) would provide similar accuracy in prediction of the development of sPEC in preterm patients with HDP (excluding sPEC).
Authors
- ER Norwitz
- DE Durie
- VF Calsavara
- JM Louis
- Y Gollin
- K Boggess
- BJ Wylie
- R Thadhani
- E Lemoine
- M Bautista
- TA Moore Simas
- RM Silver
- J Espinoza
- SA Karumanchi
- Rana S. Costantine
- A Murtha
- S Wiegand
- RK Scott
- S Kilpatrick
- SL Gaw
- AH Berg
- G Guo
- B Panda
- M Hund
- B Plunkett
- Burd
- D Singh
Publication Details
- Journal
- Obstetric Anesthesia Digest
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1097/01.aoa.0001288932.91537.77
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00